Table 1 Efficacy evaluation by tumor typea

From: PSCA-targeted BPX-601 CAR T cells with pharmacological activation by rimiducid in metastatic pancreatic and prostate cancer: a phase 1 dose escalation trial

Variable

mPDAC patients (n = 20)

mCRPC patients (n = 6)

Best overall response

CR, n (%)

0

0

PR, n (%)

0

1 (16.7%)a

uPR, n (%)

0

1 (16.7%)

SD, n (%)

12 (60%)

4 (66.7%)

PD, n (%)

8 (40%)

0

ORR, n (%)

0

1 (16.7%)

DCR, n (%)

12 (60%)

6 (100%)

  1. Prostate cancer patients with lymph node/soft tissue/visceral metastases are evaluated by RECIST v1.1 criteria regardless of bone involvement.
  2. mCRPC metastatic castration-resistant prostate cancer, mPDAC pancreatic ductal adenocarcinoma, CR complete response, PR partial response (confirmed; confirmed by repeat assessment no <4 weeks after the criteria response was first met), uPR unconfirmed partial response, SD stable disease, PD progressive disease, ORR objective response rate, DCR disease control rate.
  3. aTumor response was determined based on investigator assessment according to RECIST version 1.1. Efficacy-evaluable population consisted of patients with measurable disease who received BPX-601, at least one dose of rimiducid, and at least one post-baseline disease evaluation.
Back to article page